STI rates are rising, but with recent public health budget cuts and the effects of Covid-19, people are unable to get tested and treated. Most genitourinary medicine (GUM) clinics have closed, and those remaining offer limited services which, owing to lockdown, individuals struggle to access. Covid-19 has accelerated the shift towards remote healthcare, and Yoxly will be at the forefront of that transition
Yoxly will be the one-stop-shop for sexual health. It operates as a remote diagnostics service, offering at-home test kits and granting users peace of mind through convenience, privacy, accessibility and control. Yoxly is creating informative content and curating an online community of engaged followers, whilst exploring partnerships with organisations and advocacy groups focused on promoting sexual health. In the coming months, Yoxly aims to raise a pre-seed round in order to expand into an online pharmacy, build an app and collaborate with dating apps for seamless and positive integration between lifestyle and sexual health promotion.
Public Health England reports that the NHS spends £360M/annually on STI testing. Even when extrapolating conservatively, European (£2B) and North American (£2.8B) markets represent significantly larger opportunities.
Three independent studies estimate that the global STI diagnostics market will reach £100B by 2025, with a CAGR of nearly 9% over the next three years.
You're invited to take part in this movement. Please contact us at email@example.com.